TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:45
MorphoSys AG ( MOR ) https://www.morphosys.com
18.18USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Germany
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
MOR
350.00%
SPY
32.74%
-18.55%
MOR
SPY
92.93%
-19.98%
MOR
SPY
224.41%
MOR
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2464.10
2245.53
0.33
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
37.52
9.00
71.61
-19.63
0.00
-13.41
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-77.43
76.33
-63.70
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.5293
-25.67
-9.93
1.41
Other Earnings and Cash Flow Stats:
MorphoSys AG ( MOR ) Net Income TTM ($MM) is 18.04
MorphoSys AG ( MOR ) Operating Income TTM ($MM) is -198.85
MorphoSys AG ( MOR ) Owners' Earnings Annual ($MM) is -374.87
MorphoSys AG ( MOR ) Current Price to Owners' Earnings ratio is -6.63
MorphoSys AG ( MOR ) EBITDA TTM ($MM) is -0.20
MorphoSys AG ( MOR ) EBITDA Margin is -63.70%
Capital Allocation:
MorphoSys AG ( MOR ) has paid 0.00 dividends per share and bought back -0.044019999999989 million shares in the past 12 months
MorphoSys AG ( MOR ) has reduced its debt by 61.2069536716 million USD in the last 12 months
Capital Structure:
MorphoSys AG ( MOR ) Interest-bearing Debt ($MM) as of last quarter is 311
MorphoSys AG ( MOR ) Annual Working Capital Investments ($MM) are 64
MorphoSys AG ( MOR ) Book Value ($MM) as of last quarter is 34
MorphoSys AG ( MOR ) Debt/Capital as of last quarter is 904%
Other Balance Sheet Stats:
MorphoSys AG ( MOR ) has 200 million in cash on hand as of last quarter
MorphoSys AG ( MOR ) has 262 million of liabilities due within 12 months, and long term debt 262 as of last quarter
MorphoSys AG ( MOR ) has 136 common shares outstanding as of last quarter
MorphoSys AG ( MOR ) has 0 million USD of preferred stock value
Academic Scores:
MorphoSys AG ( MOR ) Altman Z-Score is 0.15 as of last quarter
MorphoSys AG ( MOR ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
MorphoSys AG ( MOR ) largest shareholder is TD Asset Management Inc owning 361138 shares at 6.57 ($MM) value
SIMKOWITZ DANIEL A(Head of Investment Management) Executed Type F Transaction for -55564 shares of MorphoSys AG ( MOR ) for the amount of $5198010.00 on 2022-02-24
0.00% of MorphoSys AG ( MOR ) is held by insiders, and 10.75% is held by institutions
MorphoSys AG ( MOR ) went public on 1999-03-09
Other MorphoSys AG ( MOR ) financial metrics:
FCF:-405.47
Unlevered Free Cash Flow:-330.50
EPS:-2.35
Operating Margin:-77.43
Gross Profit Margin:76.33
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-935.02
Beta:1.41
Buffet's Owners Earnings:-374.87
Price to Owner's Earnings:-6.63
About MorphoSys AG ( MOR ) :
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.